Clinical Trials Arena on MSN
BioNTech misses PFS endpoints in Phase II/III cancer vaccine trial
While PFS was not achieved in BioNTech’s cancer vaccine trial, there is still a chance for success with OS.
The company is looking to prove it can achieve significant success outside the coronavirus market.
While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 ...
After BioNTech (BNTX) announced its fixed combination vaccine, BNT113, missed one of its primary endpoints of improved progression free survival when combined with ...
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
A messenger ribonucleic acid (mRNA) vaccine against cancer failed to meet a primary goal of a late-stage clinical trial, the ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
In October 2026, BioNTech reported that its AHEAD-MERIT Phase 2/3 trial of mRNA cancer candidate BNT113 plus pembrolizumab in ...
A phase 2/3 trial of BioNTech's immunotherapy for head and neck cancer, BNT113, has failed to meet its objective, but the ...
German biotech BioNTech (Nasdaq: BNTX) has reported a setback for its experimental mRNA cancer immunotherapy BNT113 ...
2don MSN
Moderna is now worth more than 3X as much as BioNTech. Which biotech stock is the smarter pick?
Is bigger always better? Not necessarily.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results